PARP1 and cancer: Due to its strong PARP–DNA trapping ability, favorable PK properties, CNS penetration, and therapeutic potential, pamiparib was evaluated, as a monotherapy or in combination with other therapies, for the treatment of various cancers, particularly BRCA-mutated or homologous recombination-deficient tumors [1,3,4,5,6,18].